Investing.comDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 16:40:35·⟳ 抓取 16:41:28 +53s·⚡ 决策 10-25 21:08:13 +4h26m·2.0 天前
Investing.com 重发 Xencor（XNCR）XmAb819 肾癌 I 期 ESMO 数据，系同一催化的二手改写、无新增事实
72 小时内已处理记录命中同一具体催化（10-25 12:46 UTC，来源为 Xencor IR 新闻稿，结论为值得做 ENTER XNCR.US）：同一份 ESMO 2026 XmAb819 I 期数据、同一 RP3D 选择与同一 FDA/III 期注册计划。本条 Investing.com 为 AI 生成的二手媒体改写，首发更晚、事实为 IR 稿子集，仅多出 DCR 82% 与分级安全性细节（≥3 级 TRAE 72.1%、AST/ALT 升高、停药率 5.9%），这些属于同一数据读出的组成部分，不构成金额、指引、官方确认/否认或监管进展层面的新增事实，不改变前次 ENTER 结论，故作为重复信号不新增仓位。
📄 原文Investing.com↗ 原文
Xencor reports phase 1 data for cancer drug XmAb819
Why South Korea’s stock market represents the purest AI trade PASADENA, Calif. - Xencor Inc. (NASDAQ:XNCR) presented up…
不做 Xencor, Inc.（XNCR.US）
重复消息（NO_INCREMENTAL_FACT）：同一 XmAb819 ESMO 2026 I 期数据今日 12:46 UTC 已由 IR 一手稿信号研判为 ENTER，本条 Investing.com 为更晚的 AI 二手改写，除 DCR 与分级安全性明细外无新增事实，安全性细节不改变方向；不新增仓位，沿用前次决策的入场与风控安排。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Xencor XmAb819 的 ESMO I 期积极数据今日已由公司 IR 首发源处理并判定做多；Investing.com 这篇 AI 改写稿无新增可交易事实，重复信号不重复开仓。
🔎 新鲜度:最早出现 2026-10-25 · 扩散 medium · price-in 风险 low ↗
关键理由
- 前次基于 IR 一手稿的判断仍成立：400 mcg/kg 队列 cORR 45.5%、6 个月 PFS 82%，RP3D 落定且 2027 年上半年有加速批准沟通节点
- 本条补充的安全性细节（≥3 级 TRAE 72.1% 但停药率仅 5.9%）为同一读出的已知组成部分，未削弱也未增强前次逻辑
主要风险
- 小样本（n=11 可评估）、95%CI 16.8%-76.6%，且肝酶升高比例高，后续扩展数据若安全性恶化或缓解持续性不及预期将修正判断
- 周末闭市期间消息继续扩散，周一美股可能高开，前次 ENTER 的实际成交买点需按开盘承接情况执行
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-25 · 影响 none
本条新出现的安全性细节（≥3 级 TRAE 72.1%、肝酶升高约三分之一、停药率 5.9%）提示肝毒性监测负担，但停药率低，且属同一数据读出的组成部分，不构成对前次 ENTER 的证伪
检索:XmAb819 safety grade 3 AST ALT discontinuation ESMO 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变前次结论；仅决定本条不重复下单。
方向:本条按重复消息早停，不再做外部先例研究；前次 IR 源决策已完成其研判流程并给出 ENTER。
涨幅量级:不适用：重复信号不新增交易腿，不据此重定 tp/sl。
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 297 ms
{"result": "search_processed_events:agent query=`xencor phase 3 tivozanib accelerated approval fda xmab819 | xencor xmab819 phase 1 renal cell carcinoma esmo 2026 data | xncr xmab819 400 mcg/kg orr bispecific antibody clear cell `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、3341 条本臂决策(完整)，返回 1 条候选。\n• 10-25
原文全文
展开原文 · 2,013 字
Why South Korea’s stock market represents the purest AI trade
PASADENA, Calif. - Xencor Inc. (NASDAQ:XNCR) presented updated results from a Phase 1 study of XmAb819, an experimental bispecific antibody for advanced clear cell renal cell carcinoma, according to a press release statement.
The study enrolled 119 patients across 11 intravenous dose levels as of September 1, 2026. Three dose levels were evaluated in expansion cohorts: 100 mcg/kg, 200 mcg/kg, and 400 mcg/kg, with 68 patients total. Patients had received a median of three prior lines of therapy, with all having received at least one prior PD-(L)1 inhibitor and one prior VEGFR TKI.
The 400 mcg/kg cohort showed a confirmed objective response rate of 45.5% with 11 evaluable patients. The disease control rate was 82% with a median follow-up of six months. As of October 1, 2026, the six-month progression-free survival Kaplan-Meier estimate was 82% for this cohort.
Grade 3 or higher treatment-related adverse events occurred in 72.1% of patients across expansion cohorts. The most common were liver enzyme elevations, with aspartate aminotransferase increased in 35.3% and alanine aminotransferase increased in 33.8% of patients. The treatment discontinuation rate due to related adverse events was 5.9%.
Xencor selected 400 mcg/kg as the proposed recommended Phase 3 dose. The company plans to discuss a potential accelerated approval pathway with the FDA in the first half of 2027 for certain patient subgroups.
The company announced plans for a global randomized trial comparing XmAb819 with tivozanib in patients who have received prior treatment with one PD-(L)1 inhibitor and at least one VEGFR TKI. Xencor stated this study could potentially support full approval in second- and third-line treatment settings if successful.
The results were presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PASADENA, Calif. - Xencor Inc. (NASDAQ:XNCR) presented updated results from a Phase 1 study of XmAb819, an experimental bispecific antibody for advanced clear cell renal cell carcinoma, according to a press release statement.
The study enrolled 119 patients across 11 intravenous dose levels as of September 1, 2026. Three dose levels were evaluated in expansion cohorts: 100 mcg/kg, 200 mcg/kg, and 400 mcg/kg, with 68 patients total. Patients had received a median of three prior lines of therapy, with all having received at least one prior PD-(L)1 inhibitor and one prior VEGFR TKI.
The 400 mcg/kg cohort showed a confirmed objective response rate of 45.5% with 11 evaluable patients. The disease control rate was 82% with a median follow-up of six months. As of October 1, 2026, the six-month progression-free survival Kaplan-Meier estimate was 82% for this cohort.
Grade 3 or higher treatment-related adverse events occurred in 72.1% of patients across expansion cohorts. The most common were liver enzyme elevations, with aspartate aminotransferase increased in 35.3% and alanine aminotransferase increased in 33.8% of patients. The treatment discontinuation rate due to related adverse events was 5.9%.
Xencor selected 400 mcg/kg as the proposed recommended Phase 3 dose. The company plans to discuss a potential accelerated approval pathway with the FDA in the first half of 2027 for certain patient subgroups.
The company announced plans for a global randomized trial comparing XmAb819 with tivozanib in patients who have received prior treatment with one PD-(L)1 inhibitor and at least one VEGFR TKI. Xencor stated this study could potentially support full approval in second- and third-line treatment settings if successful.
The results were presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ed5eeac6a2· 2026-10-25 21:08 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前